المؤلفون: A. V. Korzun, A. V. Stoupakova, N. A. Kharitonova, A. V. Aseeva, K. O. Osipov, N. V. Pronina, E. Yu. Makarova, A. P. Vaytekhovich, A. Yu. Lopatin, M. Yu. Karpushin, Yu. D. Peregudov, R. S. Sautkin, M. A. Bolshakova, K. A. Sitar, A. S. Redkin

المصدر: Georesursy, Vol 25, Iss 2, Pp 22-35 (2024)

مصطلحات موضوعية: decarbonatization, natural reservoirs, carbon dioxide, capture, burial, storage, utilization, reservoir, aquifer, coal bed, basalt, underground gas storage, Geology, QE1-996.5

وصف الملف: electronic resource

Relation: https://www.geors.ru/jour/article/view/58; https://doaj.org/toc/1608-5043; https://doaj.org/toc/1608-5078

URL الوصول: https://doaj.org/article/fd029a23fcef498fa0b71d2e6750c6a4

المؤلفون: E. Reutova V., L. Laktionova V., D. Marinov T., D. Peregudov A., T. Borisova N., Е. Реутова В., Л. Лактионова В., Д. Маринов Т., Д. Перегудов А., Т. Борисова Н.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 176-181 ; Медицинский Совет; № 9 (2020); 176-181 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ALK translocation, non-small cell lung cancer, targeted therapy, crizotinib, транслокация ALK, немелкоклеточный рак легкого, таргетная терапия, кризотинибтранслокация ALK, кризотиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5721/5219; Sahu A., Prabhash K., Noronha V., Joshi A., Desai S. Crizotinib: A comprehensive review. South Asian J Cancer. 2013;2(2):91–97. doi:10.4103/2278-330X.110506.; Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T. et al. Firstline crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. doi:10.1056/NEJMoa1408440.; Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.-J. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886. Лактионов К.К., Артамонова Е.В., Бредер В.В., Горбунова В.А., Моисеенко Ф.В., Реутова Е.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2019;9(3s2):32–48. Режим доступа: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-01.pdf. Laktionov K.K., Artamonova E.V., Breder V.V., Gorbunova V.A., Moiseenko F.V., Reutova E.V. et al. Practical guidelines for the medicinal treatment of non-small cell cancer. Zlokachestvennye opukholi = Malignant Tumours. 2019;9(3s2):2–48. (In Russ.) Available at: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-01.pdf.; Demidova I., Grinevich V., Avdalian A., Imyanitov E., Gikalo М., Savelov et al. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches Lung Cancer. 2017;103:17–23. 10.1016/j.lungcan.2016.11.001.; Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. SOJ Thoracic Oncology. 2009;4(12):1450–1454. doi:10.1097/JTO.0b013e3181c4dedb.; Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S. et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature05945.; Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253. doi:10.1200/JCO.2009.22.6993.; Демидова И.А., Цепенщикова Е.О., Баринов А.А., Гагарин И.М., Савелов Н.А., Гриневич В.Н., Тюляндин С.А. Определение перестроек гена ALK в селектированной популяции российских больных немелкоклеточным раком легкого. Злокачественные опухоли. 2013;3(7):3–9. doi:10.18027/2224-5057-2013-3-3-9. Demidova I.A., Tepenshchikova E.O., Barinov А.А., Gagarin I.M., Savelov N.A., Grinevich V.N., Tulyandin S.A. Determination of ALK gene rearrangements in a selected population of Russian patients with non-small cell lung cancer. Zlokachestvennye opukholi = Malignant Tumours. 2013;3(7):3–9. (In Russ.) doi:10.18027/2224-5057-2013-3-3-9.; Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B. et al. Activity and safety of crizotinib in patients with ALK-positive non-smallcell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–1019. doi:10.1016/S1470-2045(12)70344-3.; Blackhall F., Ross Camidge D., Shaw A.T., Soria J.C., Solomon B.J., Mok T. et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017;2(3):e000219. doi:10.1136/esmoopen-2017-000219.; Shaw A.T., Kim T.M., Crinò L., Gridelli C., Kiura K., Liu G. et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–886. doi:10.1016/S1470-2045(17)30339-X.; Novello S., Mazières J., Oh I.J., de Castro J., Migliorino M. R., Helland Å. et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409–1416. doi:10.1093/annonc/mdy121.; Huber R.M., Hansen K.H., Paz-Ares Rodriguez L., West H.L., Reckamp K.L., Leighl N.B. et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2020;15(3):404–415. doi:10.1016/j.jtho.2019.11.004.; Solomon B.J., Besse B., Bauer T.M., Felip E., Soo R.A., Camidge D.R. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654– 1667. doi:10.1016/S1470-2045(18)30649-1.; Rangachari D., Le X., Shea M., Huberman M. S., Van der Laan P.A., Kobayashi S.S., Costa D.B. Cases of ALK-Rearranged Lung Cancer with 5-Year ProgressionFree Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017;12(11):e175-e177. doi:10.1016/j.jtho.2017.06.002.; Solomon B.J., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E. et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(22):2251–2258. doi:10.1200/JCO.2017.77.4794.; Duruisseaux M., Besse B., Cadranel J., Pérol M., Mennecier B., Bigay-Game L. et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903– 21917. doi:10.18632/oncotarget.15746.; Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.W. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–838. doi:10.1056/NEJMoa1704795.; Sakakibara-Konishi J., Kitai H., Ikezawa Y., Hatanaka Y., Sasaki T., Yoshida R. et al. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer. Clinical Lung Cancer. 2019;20(5):e555-e559. doi:10.1016/j.cllc.2019.06.021.; Shaw A.T., Friboulet L., Leshchiner I., Gainor J.F., Bergqvist S., Brooun A. et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016;374(1):54–61. doi:10.1056/NEJMoa1508887.; https://www.med-sovet.pro/jour/article/view/5721

الاتاحة: https://www.med-sovet.pro/jour/article/view/5721
https://doi.org/10.21518/2079-701X-2020-9-176-181

المؤلفون: K. Laktionov K., D. Yudin I., V. Breder V., E. Reutova V., K. Laktionov P., D. Marinov T., D. Peregudov A., M. Ardzinba S., К. Лактионов К., Д. Юдин И., В. Бредер В., Е. Реутова В., К. Лактионов П., Д. Маринов Т., Д. Перегудов А., М. Ардзинба С.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2019); 110-114 ; Медицинский Совет; № 10 (2019); 110-114 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-10

مصطلحات موضوعية: NSCLC, EGFR, tyrosine kinase inhibitors, integrated chemotherapy, НМРЛ, ингибиторы тирозинкиназы, интегрированная химиотерапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/3060/2984; Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13(3):239-246.; Sequist L.V., Yang J.C., Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334.; Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.; Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis. PLOS ONE. 2013 November 8;8(Issue 11):e79000. www.plosone.org; Kanda S., Horinouchi H., Fujiwara Y., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Kubota K., Tamura T., Ohe Y. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 2015 Sep;89(3):287-93.; Soria J.-C., Ohe Y., Vansteenkiste J. et al. FLAURA Investigators. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;278(2):113-125.; Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932–20937.; Engleman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O. et al. MET amplification leads to gefitinib resistance in lung cancer by activation ERBB3 signaling. Science. 2007;316:1039–1043.; Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247.; Soria J.C., Wu Y.L., Nakagawa K. et al. Gefi tinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-smallcell lung cancer after progression on first-line gefi tinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–98.; Saito H., Fukuhara T. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous nonsmall- cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625–35.; Nakamura A., Inoue A. et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Journal of Clinical Oncology. 2018 May 20;36(15_suppl):9005-9005.; https://www.med-sovet.pro/jour/article/view/3060

الاتاحة: https://www.med-sovet.pro/jour/article/view/3060
https://doi.org/10.21518/2079-701X-2019-10-110-114

المؤلفون: К. LAKTIONOV К., М. PEREGUDOVA V., V. BREDER V., E. REUTOVA V., D. PEREGUDOV A., M. ARDZINBA S., P. CHERNENKO A., D. MARINOV T., К. ЛАКТИОНОВ К., М. ПЕРЕГУДОВА В., В. БРЕДЕР В., Е. РЕУТОВА В., Д. ПЕРЕГУДОВ А., М. АРДЗИНБА С., П. ЧЕРНЕНКО А., Д. МАРИНОВ Т.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2016); 66-72 ; Медицинский Совет; № 10 (2016); 66-72 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2016-10

مصطلحات موضوعية: non-small-cell lung cancer, adenocarcinoma, EGFR mutation, Del19, L858R, afatinib, немелкоклеточный рак легкого, аденокарцинома, мутация гена EGFR, афатиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1407/1365; Imyanitov EN, Demidova IA, Gordiev MG et al. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Molecular Diagnosis & Therapy, 2016 Aug, 20(4): 401-6.; Reguart N, Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced nonsmall- cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors. 10.2217/ FON.15.15 © 2015 Future Medicine Ltd.; Mok T, Wu Y-L, Throngprasert S et al. Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 2009, 361: 947-957.; Han JY, Park K, Kim SW et al. First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung; Journal of Clinical Oncology, 2012, 30:1122-8. doi:10.1200/JCO.2011.36.8456.; Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factorreceptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, 2010, 11: 121-128.; Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for Non-Small-Cell lung cancer with mutated EGFR. The New England Journal of Medicine, 2010, 362: 2380- 2388.; Zhou C, Wu Y-L, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall- cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, 2011, 12: 735-742.; Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standart chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 2012, 13: 239-246.; Chih-Hsin Yang J et al. Afatinib versus cisplatin- based chemotherapy for EGFR mutationpositive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, 2015, 16(2): 141-151. DOI:10.1016/S1470-2045(14)71173-8.; Solca F, Dahl G, Zoephel A, Bader G , Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. Target binding properties and cellular activity of afatinib (BBW 2992), in irreversible ErbB family blocker. J Pharmacol Exp Ther, 2012,343: 342-350.; Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27: 4702-11.; Modjtahedi H et al. A comprehensive review of the preclinical efficacy profile of the ErbB familyblocker afatinib in cancer. Naunyn-Schmiedeberg’sArch Pharmacol, 2014, 387:505-521.; Горбунова В.А. Афатиниб – первый селективный необратимый ингибитор семейства ErbB. Эффективная Фармакотерапия. Онкология, гематология и радиология, 2014, 2(37): 20-28./ Gorbunova V.A. Afatinib is the first selective non-eversible nhibitor of ErbB family. Effektivnaya Farmakoterapia. Onkologia, Gematologia I Radiologia, 2014, 2(37): 20-28.; Sequist L, Chih-Hsin Yang J, Yamamoto N et al. Phase III study of afatinib or cisplatin pluspemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol., 2013, 31: 3327-3334.; Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for fi rst-line treatment of Asian patients with advanced nonsmall- cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15: 213-22.; Keunchil Park, Eng-Huat Tan et al. Afatinib versus gefi tinib as fi rst-line treatment of patients with EGFR mutation-positive nonsmall-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomized controlled trial. Lancet Oncol, 2016, 17: 577-89.; Hall PE, Spicer J, Popat S. Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncol, 2015, 11(15): 2175-2191.; Schuler M, Yang JC-H et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology 00: 1-7, 2016. doi:10.1093/annonc/mdv597.; Онкология. Клинические рекомендации под редакцией академика РАН Давыдова М.И. Москва 2015./Oncology Clinical Recommendations ed. By Academician of RAS Davydov M.I.; «Федеральные клинические рекомендации по диагностике и лечению больных раком легкого». Ассоциация онкологов России. Москва 2014г. http://www.oncology.ru/association/ clinical-guidelines/2014/small-cell-lungcancer/. Federal Clinical Recommendations on Diagnostics and Therapy of Pulmonary Cancer. Russian Oncologist Association. Moscow 2014. http://www.oncology.ru/association/clinicalguidelines/ 2014/small-cell-lung-cancer/; NCCN Clinical Practice Guidelines in Oncology “Non-Small Cell Lung Cancer. Version 4.2016. http://www.nccn.org/professionals/physician_ gls/pdf/nscl.pdf.; Reck M, Popat S et al. ESMO Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. Ann Oncol, 2014, 25(suppl 3): iii27-iii39. http://www.esmo.org/Guidelines/Lung- ancer/ Metastatic-Non-Small-Cell-Lung-Cancer.; Masters GA, Temin S et al. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Published online ahead of print at www.jco.org on August 31, 2015. doi:10.1200/JCO.2014.60.6624 Clin Oncol, 33. © 2015 by American Society of Clinical Oncology.; https://www.med-sovet.pro/jour/article/view/1407

الاتاحة: https://www.med-sovet.pro/jour/article/view/1407
https://doi.org/10.21518/2079-701X-2016-10-66-72